These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 32004094)

  • 1. Twenty-Five Years of Spinal Muscular Atrophy Research: From Phenotype to Genotype to Therapy, and What Comes Next.
    Wirth B; Karakaya M; Kye MJ; Mendoza-Ferreira N
    Annu Rev Genomics Hum Genet; 2020 Aug; 21():231-261. PubMed ID: 32004094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
    Chen TH
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype.
    Hosseinibarkooie S; Peters M; Torres-Benito L; Rastetter RH; Hupperich K; Hoffmann A; Mendoza-Ferreira N; Kaczmarek A; Janzen E; Milbradt J; Lamkemeyer T; Rigo F; Bennett CF; Guschlbauer C; Büschges A; Hammerschmidt M; Riessland M; Kye MJ; Clemen CS; Wirth B
    Am J Hum Genet; 2016 Sep; 99(3):647-665. PubMed ID: 27499521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA; Talbot K; Bowerman M
    Hum Mol Genet; 2017 Oct; 26(R2):R151-R159. PubMed ID: 28977438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutics development for spinal muscular atrophy.
    Sumner CJ
    NeuroRx; 2006 Apr; 3(2):235-45. PubMed ID: 16554261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
    Janzen E; Mendoza-Ferreira N; Hosseinibarkooie S; Schneider S; Hupperich K; Tschanz T; Grysko V; Riessland M; Hammerschmidt M; Rigo F; Bennett CF; Kye MJ; Torres-Benito L; Wirth B
    Brain; 2018 Aug; 141(8):2343-2361. PubMed ID: 29961886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis.
    Riessland M; Kaczmarek A; Schneider S; Swoboda KJ; Löhr H; Bradler C; Grysko V; Dimitriadi M; Hosseinibarkooie S; Torres-Benito L; Peters M; Upadhyay A; Biglari N; Kröber S; Hölker I; Garbes L; Gilissen C; Hoischen A; Nürnberg G; Nürnberg P; Walter M; Rigo F; Bennett CF; Kye MJ; Hart AC; Hammerschmidt M; Kloppenburg P; Wirth B
    Am J Hum Genet; 2017 Feb; 100(2):297-315. PubMed ID: 28132687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies for spinal muscular atrophy: SMN and beyond.
    Bowerman M; Becker CG; Yáñez-Muñoz RJ; Ning K; Wood MJA; Gillingwater TH; Talbot K;
    Dis Model Mech; 2017 Aug; 10(8):943-954. PubMed ID: 28768735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances and Clinical Applications of Exon Inclusion for Spinal Muscular Atrophy.
    Son HW; Yokota T
    Methods Mol Biol; 2018; 1828():57-68. PubMed ID: 30171534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice.
    Strathmann EA; Peters M; Hosseinibarkooie S; Rigo FW; Bennett CF; Zaworski PG; Chen KS; Nothnagel M; Wirth B
    PLoS One; 2018; 13(9):e0203398. PubMed ID: 30188931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neuromuscular impact of symptomatic SMN restoration in a mouse model of spinal muscular atrophy.
    Arnold W; McGovern VL; Sanchez B; Li J; Corlett KM; Kolb SJ; Rutkove SB; Burghes AH
    Neurobiol Dis; 2016 Mar; 87():116-23. PubMed ID: 26733414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling.
    Wirth B; Herz M; Wetter A; Moskau S; Hahnen E; Rudnik-Schöneborn S; Wienker T; Zerres K
    Am J Hum Genet; 1999 May; 64(5):1340-56. PubMed ID: 10205265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy.
    Singh NN; Lee BM; DiDonato CJ; Singh RN
    Future Med Chem; 2015; 7(13):1793-808. PubMed ID: 26381381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal muscular atrophy: state-of-the-art and therapeutic perspectives.
    Wirth B
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Jun; 3(2):87-95. PubMed ID: 12215230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moving towards treatments for spinal muscular atrophy: hopes and limits.
    Wirth B; Barkats M; Martinat C; Sendtner M; Gillingwater TH
    Expert Opin Emerg Drugs; 2015 Sep; 20(3):353-6. PubMed ID: 25920617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease mechanisms and therapeutic approaches in spinal muscular atrophy.
    Tisdale S; Pellizzoni L
    J Neurosci; 2015 Jun; 35(23):8691-700. PubMed ID: 26063904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In Vitro Evaluation of Antisense-Mediated Exon Inclusion for Spinal Muscular Atrophy.
    Touznik A; Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():439-454. PubMed ID: 30171558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases.
    Calucho M; Bernal S; Alías L; March F; Venceslá A; Rodríguez-Álvarez FJ; Aller E; Fernández RM; Borrego S; Millán JM; Hernández-Chico C; Cuscó I; Fuentes-Prior P; Tizzano EF
    Neuromuscul Disord; 2018 Mar; 28(3):208-215. PubMed ID: 29433793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.